/
/
/

Sudarshan Pharma Industries Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
--12%9%
--45%39%
--66%33%
13%13%12%13%

Peer Comparison

Symbol
SUNPHARMA-A
DIVISLAB-A
TORNTPHARM-A
ZYDUSLIFE-A
LAURUSLABS-A
CIPLA-A
DRREDDY-A
MANKIND-A
AUROPHARMA-A
LUPIN-A
SUDARSHAN-M
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,748.9₹424466 Cr35.0912.0762.82₹11479 Cr
9,029.85₹246222 Cr84.1834.04128.41₹2568 Cr
4,594₹176301 Cr80.8316.7297.06₹2163 Cr
1,124₹112818 Cr259.4262.53₹5040 Cr
2,036₹110823 Cr101.366.829.25₹889 Cr
1,312.85₹107447 Cr31.889.7757.87₹3879 Cr
1,214.1₹103471 Cr32.115.3263.99₹4196 Cr
2,330.1₹97850 Cr47.913.7571.08₹1913 Cr
1,659.9₹96836 Cr26.0817.9596.84₹3505 Cr
1,954.8₹89629 Cr16.2130.95154.35₹5333 Cr
36.6₹954 Cr37.950.231.16₹23 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
₹174 Cr₹221 Cr₹168 Cr₹169 Cr₹145 Cr₹162 Cr₹116 Cr₹129 Cr₹99 Cr
₹1 Cr₹4 Cr₹2 Cr₹2 Cr₹1 Cr₹84 L₹51 L₹32 L₹98 L
₹176 Cr₹225 Cr₹170 Cr₹171 Cr₹146 Cr₹162 Cr₹116 Cr₹129 Cr₹100 Cr
₹160 Cr₹202 Cr₹158 Cr₹161 Cr₹135 Cr₹146 Cr₹108 Cr₹116 Cr₹98 Cr
₹17 Cr₹24 Cr₹12 Cr₹11 Cr₹12 Cr₹17 Cr₹8 Cr₹13 Cr₹3 Cr
₹8 Cr₹8 Cr₹6 Cr₹6 Cr₹6 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr
₹8 Cr₹16 Cr₹5 Cr₹4 Cr₹5 Cr₹10 Cr₹4 Cr₹8 Cr-₹2 Cr
₹6 Cr₹11 Cr₹4 Cr₹4 Cr₹4 Cr₹7 Cr₹3 Cr₹6 Cr-₹1 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
—————
₹24 Cr₹24 Cr₹24 Cr₹10 Cr₹10 Cr
₹4 Cr₹0₹0₹0₹0
₹104 Cr₹88 Cr₹77 Cr₹20 Cr₹13 Cr
₹104 Cr₹88 Cr₹77 Cr₹20 Cr₹13 Cr
₹131 Cr₹112 Cr₹101 Cr₹30 Cr₹23 Cr
₹7,000₹0₹0₹0₹5 L
₹10 Cr₹9 Cr₹12 Cr₹4 Cr₹3 Cr
₹55 L₹1 Cr₹1 Cr₹86 L₹3 Cr
₹29 L₹2 L₹18 L₹14 L₹14 L
₹49 L₹42 L₹6 L₹4 L₹3 L
₹11 Cr₹11 Cr₹13 Cr₹5 Cr₹5 Cr
—————
₹92 Cr₹57 Cr₹92 Cr₹74 Cr₹44 Cr
₹6 Cr₹10 Cr₹8 Cr₹5 Cr₹5 Cr
₹157 Cr₹91 Cr₹18 Cr₹24 Cr₹21 Cr
₹5 Cr₹3 Cr₹71 L₹39 L₹28 L
₹260 Cr₹160 Cr₹118 Cr₹103 Cr₹71 Cr
₹402 Cr₹283 Cr₹232 Cr₹138 Cr₹99 Cr
₹29 Cr₹40 L₹20 L₹19 L₹2 L
₹171 Cr₹105 Cr₹34 Cr₹31 Cr₹30 Cr
—————
₹30 Cr₹29 Cr₹22 Cr₹8 Cr₹8 Cr
₹6 Cr₹4 Cr₹3 Cr₹2 Cr₹1 Cr
₹24 Cr₹26 Cr₹20 Cr₹6 Cr₹6 Cr
₹6 Cr₹2 Cr₹1 L₹54 L₹0
₹29 Cr₹12 Cr₹12 Cr₹22,000₹22,000
₹29 Cr₹12 Cr₹12 Cr₹22,000₹22,000
₹5 Cr₹2 Cr₹2 Cr₹94 L₹5 Cr
₹4 Cr₹4 Cr₹0₹0₹0
₹68 Cr₹46 Cr₹34 Cr₹8 Cr₹12 Cr
—————
₹2 Cr₹2 Cr₹0₹0₹0
₹140 Cr₹86 Cr₹75 Cr₹47 Cr₹24 Cr
₹160 Cr₹123 Cr₹82 Cr₹73 Cr₹60 Cr
₹55 L₹14 L₹12 Cr₹24 L₹1 Cr
₹3 Cr₹10 Cr₹1 Cr₹45 L₹43 L
₹29 Cr₹18 Cr₹30 Cr₹9 Cr₹2 Cr
₹335 Cr₹237 Cr₹199 Cr₹130 Cr₹88 Cr
₹75 Cr₹77 Cr₹80 Cr₹27 Cr₹16 Cr
₹402 Cr₹283 Cr₹232 Cr₹138 Cr₹99 Cr
₹5₹46₹42₹31₹24
₹5₹5₹42₹31₹24

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent of Subsidiaries under liquidations
Closing Cash & Cash Equivalent
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
₹22 Cr₹15 Cr₹9 Cr₹7 Cr₹4 Cr
₹20 Cr₹9 Cr₹6 Cr₹4 Cr₹4 Cr
-₹3 Cr-₹15 Cr-₹42 Cr-₹13 Cr-₹4 Cr
₹38 Cr₹10 Cr-₹27 Cr-₹2 Cr₹4 Cr
₹35 Cr₹8 Cr-₹29 Cr-₹4 Cr₹3 Cr
-₹20 Cr-₹7 Cr-₹26 Cr-₹1 Cr-₹1 Cr
-₹14 Cr-₹12 Cr₹66 Cr₹4 Cr-₹1 Cr
₹37 L-₹12 Cr₹11 Cr-₹1 Cr-₹1 L
₹14 L₹12 Cr₹24 L₹1 Cr₹1 Cr
₹4 L₹15,000₹0₹0₹0
₹55 L₹14 L₹12 Cr₹24 L₹1 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)37.99
Volume (₹)72,000.00
High (₹)37.99
Upper Circuit41.21
Low (₹)36.51
Lower Circuit33.73
Prev Close37.47
52W High (₹)42.79
Price36.60
52W Low (₹)18.50

Share Market Cap & Key Ratios Overview

M.Cap (₹)953.50 Cr
Div. Yield (%)0.00
PE Ratio37.95
Debt to Equity1.34
Price to Book5.76
Book Value5.30
EPS (TTM)0.99
Face Value1.00
ROE (%)13.33

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
LAURUSLABS-ANSE
CIPLA-ANSE
DRREDDY-ANSE
MANKIND-ANSE
AUROPHARMA-ANSE
LUPIN-ANSE
SUDARSHAN-MNSE
LTP
1W Low
1W High
Market cap (₹)
1748.9-8 (-0.46%)
1725.70
1777.05
4,24,466Cr
9029.85-296.15 (-3.18%)
8938
9450
2,46,222Cr
4594-66 (-1.42%)
4557.10
4680.30
1,76,301Cr
1124+8.9 (0.80%)
1108
1150.90
1,12,818Cr
2036+3.9 (0.19%)
2008.70
2071
1,10,823Cr
1312.85+9.55 (0.73%)
1300.25
1330.60
1,07,447Cr
1214.1+19 (1.59%)
1195.65
1250.95
1,03,471Cr
2330.1-38.9 (-1.64%)
2317.80
2425.05
97,850Cr
1659.9-26.2 (-1.55%)
1654.70
1714.90
96,836Cr
1954.8-5.2 (-0.27%)
1925.85
1966.05
89,629Cr
36.6-0.92 (-2.45%)
36.51
38.71
954Cr

Sudarshan Pharma Industries Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹17.12Cr; with other income of ₹1.22Cr, profit before interest and tax came to ₹15.71Cr. Interest expense was ₹8.21Cr; PBT before exceptional items stood at ₹7.51Cr. Cost mix (full year): raw materials ₹491.1Cr; employee cost ₹3.45Cr; depreciation ₹1.41Cr; other expenses ₹158.52Cr. Basis: consolidated annual results.

Sudarshan Pharma Industries Ltd Quaterly Results Key Takeaways

Sudarshan Pharma Industries Ltd reported ₹174.42Cr total income from operations in Jun 2026, softer than ₹220.92Cr in Mar 2026 but higher than ₹145.26Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹17.12Cr; with other income of ₹1.22Cr, profit before interest and tax came to ₹15.71Cr. Interest expense was ₹8.21Cr, taking profit before tax to ₹7.51Cr. After tax of ₹1.9Cr, profit after tax stood at ₹5.61Cr (vs ₹11.39Cr in Mar 2026 and ₹3.96Cr in Jun 2025).